Skip to main content
OpenTrials
Recruiting

NCT Number: NCT05324475

Maintaining Immune and Mitochondrial Functions in Old Adults With SAfe Nutrition.

Aging is associated with an increased inflammation named "inflammageing" and with an altered immune response. Different mechanisms have been proposed to explain the phenomenon of inflammageing and increased oxidative stress: deficiencies in essential amino acids, and some micronutrients have an important impact and may induce immune cell dysregulation. Mitochondrial dysfunction may explain the complex relationship between malnutrition sarcopenia, immune dysfunction and aging.

Therefore, a personalized nutritional strategy aiming to improve mitochondrial function, decrease oxidative stress, down-regulate inflammation and restore immunity appears to be a logical approach in order to treat malnutrition and its biological and clinical consequences.

MIMOSA will investigate the role of nutritional supplements in rescuing altered mitochondrial function and redox state imbalance.

Recruiting

Interested in participating?

Request Info

Key information

Age range

75 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

About this study

The study participants will all receive optimal standard care ensuring the optimal protein and energy intakes, with at least 1 g protein per kg body weight and day, and 30 kcal per kg body weight and day (or the measured energy expenditure (EE) value). This will be realized by the daily administration of oral nutritional supplements (ONS) providing whole proteins together with dietary advice [according with the ESPEN nutrition guidelines. All the patients will receive the standard commercially available product used at CHUV (Resource protein ®, Nestlé) and nutritional counselling (SC).

All participants included in this study will receive daily, the oral nutritional supplement (ONS), one sachet and two capsule (for blinding purpose).

The intervention nutrients will be delivered as follows:

  • BCAA: 1 sachet containing 4 g of BCAA (details in Table 1)
  • Micronutrients: 1 sachet containing 4 g of the micronutrient blend and 2 capsules containing 0.6 g of OMEGA 3 PUFA (details in table 1).

The placebos will be delivered like this:

-1 sachet containing 1 g of maltodextrin and 2 capsules containing 0.6 g of coconut oil. (detailed in Table 1).

The duration of the intervention will be 6 weeks, but at least 4 weeks After enrollment patients will be subjected to evaluation of muscle mass by bioimpedance (BIA), muscle strength will be by handgrip strength and muscle performance by the Short Performance Physical Battery (SPPB).

Nutritional status will be evaluated by the Mini Nutritional Assessment short form (MNA-SF), Nutrition Risk screening (NRS) score and Body mass index (BMI). Energy expenditure (EE) will be measured by indirect calorimetry using a canopy.

Moreover appropriate experiments will be carried out in order to evaluate mitochondrial bioenergetics, replication, and fusion, as well as of redox state.

Analyses of inflammageing and immune-senescence will be done by appropriate lab experiments.

Micronutrient status will be measured by ELISA or HPLC and ICPMS respectively. Patients will be evaluated at inclusion, at rehabilitation discharge, and one and two months after rehabilitation discharge. The volume of blood required for the above investigations will be 3 x 30 ml over the 2-month period.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Age ≥75 years
  • Patients entering a rehabilitation program
  • Diagnosis of malnutrition defined by a MNA-SF (mini-nutritional assessment short form) score below 11 points.
  • Commitment to accept the nutritional supplement proposed, willing and able to give written informed consent
  • Ability to understand and comply with the requirements of the study

Exclusion criteria

  • Presence of malignancy,
  • Life expectancy of less than two months calculated by Multidimensional Prognostic Index (MPI ),
  • Congestive heart failure (NYHA IV),
  • Chronic renal disease (creatinine clearance <40 ml/min calculated by cockroft),
  • Liver cirrhosis (Child B-C),
  • Tube/percutaneous endoscopic gastrostomy feeding or parenteral nutrition,
  • Severe dysphagia,
  • Mini-Mental State Examination (MMSE)≤18 and MNA>11 points. MMSE ≥ 18 identifies patients with mild form of cognitive impairment; those patients generally do not have problems in swallowing and are able to take drugs.
  • Severe anaemia (Hb<10 g/l) or leukopenia (<2G/l).

Treatment and study plan

BCAA

Dietary Supplement

daily administration of oral nutritional supplements (ONS) 1) providing whole proteins together with dietary advice according with the ESPEN nutrition guidelines. All the patients will receive the standard commercially available product used at CHUV (Resource protein ®, nestle) and nutritional counselling (SC) and 4 gram per day of BCAAs mixture. Ratio between the BCAAs will be Leucine/Isoleucine/Valine=2:1:1

Micronutriments

Dietary Supplement

daily administration of oral nutritional supplements (ONS) 1) providing whole proteins together with dietary advice according with the ESPEN nutrition guidelines. All the patients will receive the standard commercially available product used at CHUV (Resource protein ®, nestle ) and nutritional counselling (SC) and Vitamin A 1200 mg RE, Vitamin D3 2000 IU, Thiamine B1 100 mg, Cobalamin B12 10 mcg, Ascorbic acid C 200 mg, Iron 30 mg, Selenium 100 mcg, Zinc 20 mg, Omega-3 PUFA 1 g

standard treatment + placebo

Dietary Supplement

daily administration of oral nutritional supplements (ONS) 1) providing whole proteins together with dietary advice according with the ESPEN nutrition guidelines. All the patients will receive the standard commercially available product used at CHUV (Resource protein ®, nestle ) and nutritional counselling (SC) and maltodextrin 4 g as placebo

Primary outcomes

  1. Change in mitochondrial ATP production (nmol/ml)

    Time frame: change vesus baseline at 30, 60 days after discharge

    Production of ATP will be measured using the ATP Bioluminescent Assay Kit

  2. Change in redox state (plasmatic concentration of metabolites)

    Time frame: change vesus baseline at 30, 60 days after discharge

    analyses of thiometabolome contains: methionine, methionine sulfone, methionine sulfoxide, cysteine, homocysteine, homocystine, cystathionine, formylmethionine, cystine, glutathione, glutathione disulfide, taurine, S-adenosylmethionine, S-adenosylhomocysteine, N-acetylcysteine, cysteic acid, serine, glycine, glutamic acid, lypoic acid, selenocysteine, thioctic acid, pyruvic acid.

  3. Change in mitochondrial electron flux (nmol cit/min/mg prot)

    Time frame: change vesus baseline at 30, 60 days after discharge

    The activity of Complex I and III will be measured on non-sonicated mitochondrial samples

Secondary outcomes

  1. change micronutrients status (concentration of micronutrients)

    Time frame: change versus baseline at 60 days after discharge

    Blood levels of Vitamins A, B12, D and E, as well as of trace elements Cu, Fe, Se, and Zn will be determined by ELISA or HPLC and ICPMS

  2. change in inflammation

    Time frame: change versus baseline at 30, 60 days after discharge

    Production of pro-inflammatory cytokines involved in inflammageing and in muscle waste will be measured by ELISA technique; we will measure IL-6 and TNF-alpha (pg/ml).

  3. change phase angle (score)

    Time frame: change versus baseline at rehab discarge (21 days), 30, 60 days after discharge

    Bioelectrical impedance analysis (BIA) will be carried out

  4. muscle function (score)

    Time frame: change versus baseline at rehab discarge (21 days), 30, 60 days after discharge

    Short performance physical battery will be used to measure muscle performance

  5. muscle mass (Kg/body weight)

    Time frame: change versus baseline at rehab discarge (21 days), 30, 60 days after discharge

    Bioelectrical impedance analysis (BIA) will be used to measure muscle mass

  6. muscle strength (Kg)

    Time frame: change versus baseline at rehab discarge (21 days), 30, 60 days after discharge

    Hand grip will be used to measure muscle strenght

  7. change in perceived health status (score)

    Time frame: change versus baseline at rehab discarge (21 days), 30, 60 days after discharge

    questionnaire

Study contacts

Contact information is provided by the study sponsor or research team.

Patrizia D'amelio

CONTACT

[email protected]

+41213143712

Sponsors and collaborators

Lead sponsor

Patrizia D'Amelio

Other

Registry information

Official study title

Maintaining Immune and Mitochondrial Functions in Old Adults With SAfe Nutrition: the MIMOSA Study.

Acronym: MIMOSA

Important dates

Study start
2025
Primary completion
2027
Study completion
2028
First posted
Apr 12, 2022
Registry last updated
May 31, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.